Investigational site
Ruddington, Nottingham, United Kingdom
NCT Number: NCT02293967
The purpose of this study is to investigate the absorption, metabolism and excretion of MT-1303 in healthy subjects.
Looking for future studies?
Notify Me30 year–65 year
Male
Interventional
Phase 1
Ruddington, Nottingham, United Kingdom
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: up to 10 weeks
Time frame: up to 10 weeks
Tanabe Pharma Corporation
Industry
An Open-label, Mass Balance Study to Investigate the Absorption, Metabolism and Excretion of [14C] MT-1303 After a Single Oral Dose to Healthy Male Subjects.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02283853
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Boston, Massachusetts, United States
View Trial DetailsNCT01805336
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Caen, Basse-Normandie, France
View Trial DetailsNCT04940065
Active Secondary Progressive Multiple Sclerosis, Autoimmune Diseases
Ichinomiya, Aichi-ken, Japan
View Trial DetailsNCT07002151
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Cairo, Egypt
View Trial Details